Harpera Microbiopsy Device Receives FDA Registration: A Breakthrough in Skin Science Innovation

The Harpera microbiopsy device, a groundbreaking innovation developed by Molecular Twins founder Professor Tarl Prow, has recently been registered with the FDA as a medical device, a milestone that marks a seismic shift in how skin sampling is conducted. This revolutionary tool offers minimally invasive, high-precision skin sampling, removing the barriers of traditional punch biopsies and unlocking new frontiers in dermatological research, drug development, and personalized medicine.

The future of skin sampling

Traditional skin biopsies are invasive, painful, and often deter study participation due to discomfort, and extended healing times, particularly if sutures are required. These limitations have long slowed down skin research, restricted participant diversity and scope, and increased costs for clinical studies.

Recognizing these challenges, our co-CEO, Professor Tarl Prow, led the development of the Harpera microbiopsy device - a virtually painless, non-scarring alternative to traditional biopsy methods. Laser-cut from medical-grade stainless steel, this device enables the collection of thousands of cells from the skin’s epidermis and upper dermis with minimal discomfort, making high-quality molecular data collection faster, safer, and more accessible than ever before.

Now, with FDA registration, the device is ready to reshape the landscape of skin research and clinical trials, offering unprecedented advantages to pharma, biotech, and consumer health innovators.

Why this is a game-changer for skin science and innovation

With the Harpera microbiopsy device, Molecular Twins is transforming how research is conducted, how trials are designed, and how innovation reaches patients.

1. Unparalleled research capabilities

• Enables longitudinal studies without causing patient discomfort, allowing researchers to track disease progression and treatment response over time, even in sensitive areas such as the face.
• Unlocks deeper transcriptomic insights, fueling the development of precision dermatology, drug discovery, and next-generation skin therapies.

2. Expanding access and study diversity

• Removes traditional barriers to participation, allowing broader, more representative populations to engage in clinical research.
• Makes high-quality molecular data collection accessible in real-world settings, increasing the scale and impact of dermatological studies.

3. Pioneering personalized skin medicine

• Enables high-resolution biomarker profiling, allowing for hyper-personalized treatment strategies in dermatology, immunology, and regenerative medicine.
• Accelerates the development of tailored skincare, pharmaceuticals, and advanced skin-interfacing medical devices.

What FDA registration means for our partners

With FDA registration, Molecular Twins is now delivering Harpera microbiopsy technology to pharma, biotech, and consumer health partners worldwide. This means:

✅ More efficient and cost-effective clinical studies – reduce dropout rates, increase data reliability, and accelerate research timelines.

✅ Better patient and consumer engagement – non-invasive sampling improves compliance, making studies more scalable and impactful.

✅ Faster drug and product development – generate high-quality molecular data that feeds into our BioIntelligence platform, powering AI-driven analysis, pathway mapping, and predictive modeling.

This is a revolution in skin research.

What’s next? Building the future of skin science

At Molecular Twins we’re building a world-first, AI-powered intelligence platform that turns transcriptomics data into real-time, actionable insights.

With Harpera microbiopsy at the forefront, we’re pioneering a new era of dermatological research, drug discovery, and personalized skincare innovation. Our partners will have access to the most advanced skin science tools available, enabling smarter clinical trials, deeper scientific exploration, and accelerated innovation.

Want to leverage Harpera microbiopsy for your next study? Let’s talk.

‍